Literature DB >> 24649032

miR-141 and miR-375 induction and release are different from PSA mRNA and PCA3 upon androgen stimulation of LNCaP cells.

Duygu Tiryakioglu1, Elif Bilgin1, Stefan Holdenrieder2, Nejat Dalay1, Ugur Gezer1.   

Abstract

Recent studies have demonstrated the differential expression of miR-141 and miR-375 in circulation of patients with advanced/metastatic prostate cancer (PCa). The aim of this study was to investigate the regulation of miR-141 and miR-375 by androgens and their release into the incubation medium in relation to prostate-specific antigen (PSA) mRNA and prostate cancer antigen 3 (PCA3). Plasma levels of these molecules were measured in a small cohort of patients with localized PCa. As an in vitro cell model we used androgen-sensitive LNCaP cells exposed to an androgen ablation of 48 h, and then treated with dihydrotestosterone (DHT) for 24 h. Expression of the four RNA molecules was measured by quantitative polymerase chain reaction (qPCR). miR-141 and miR-375 were induced in a dose-dependent manner where the median stimulation reached only 1.5-fold at maximum. The effect of DHT on PSA mRNA (up to 30-fold) and PCA3 (up to 195-fold) was much more evident. With regard to the release into the incubation medium, similar results were obtained with the exception of PCA3. At the highest DHT dose (100 nM), median miR-141 and miR-375 release was increased 1.7- and 1.4-fold (P=0.07), respectively. DHT treatment led to a significant release of PSA mRNA (up to 12-fold) into the medium while PCA3 could not be amplified from the incubation medium. In plasma only PCA3 differed significantly between localized PCa patients and healthy subjects. In conclusion, our study provides evidence that miR-141 and miR-375 are increasingly released into incubation medium from androgen-stimulated cells. However, the extent of their induction was weaker than PSA mRNA or PCA3, suggesting differential regulation by androgens.

Entities:  

Keywords:  androgens; microRNAs; molecule release; prostate cancer

Year:  2013        PMID: 24649032      PMCID: PMC3917051          DOI: 10.3892/br.2013.135

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  18 in total

Review 1.  Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis.

Authors:  Nobuyoshi Kosaka; Haruhisa Iguchi; Takahiro Ochiya
Journal:  Cancer Sci       Date:  2010-07-07       Impact factor: 6.716

2.  Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program.

Authors:  Matthew J Hayat; Nadia Howlader; Marsha E Reichman; Brenda K Edwards
Journal:  Oncologist       Date:  2007-01

3.  miR-141 modulates androgen receptor transcriptional activity in human prostate cancer cells through targeting the small heterodimer partner protein.

Authors:  Jing Xiao; Ai-Yu Gong; Alex N Eischeid; Dongqing Chen; Caishu Deng; Charles Y F Young; Xian-Ming Chen
Journal:  Prostate       Date:  2012-02-07       Impact factor: 4.104

4.  Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer.

Authors:  Fulya Yaman Agaoglu; Müge Kovancilar; Yavuz Dizdar; Emin Darendeliler; Stefan Holdenrieder; Nejat Dalay; Ugur Gezer
Journal:  Tumour Biol       Date:  2011-01-28

5.  Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer.

Authors:  Jason C Gonzales; Louis M Fink; Oscar B Goodman; James T Symanowski; Nicholas J Vogelzang; David C Ward
Journal:  Clin Genitourin Cancer       Date:  2011-07-01       Impact factor: 2.872

6.  Molecular characterization of human prostate carcinoma cell lines.

Authors:  Adrie van Bokhoven; Marileila Varella-Garcia; Christopher Korch; Widya U Johannes; E Erin Smith; Heidi L Miller; Steven K Nordeen; Gary J Miller; M Scott Lucia
Journal:  Prostate       Date:  2003-11-01       Impact factor: 4.104

7.  Increased UDP-glucuronosyltransferase activity and decreased prostate specific antigen production by biochanin A in prostate cancer cells.

Authors:  X Y Sun; C A Plouzek; J P Henry; T T Wang; J M Phang
Journal:  Cancer Res       Date:  1998-06-01       Impact factor: 12.701

8.  Prostate cancer antigen 3 (PCA3) RNA detection in blood and tissue samples for prostate cancer diagnosis.

Authors:  Adriana F Neves; Jaqueline D Dores Dias-Oliveira; Thaise G Araújo; Karina Marangoni; Luiz R Goulart
Journal:  Clin Chem Lab Med       Date:  2013-04       Impact factor: 3.694

9.  Changes in circulating microRNA levels associated with prostate cancer.

Authors:  R J Bryant; T Pawlowski; J W F Catto; G Marsden; R L Vessella; B Rhees; C Kuslich; T Visakorpi; F C Hamdy
Journal:  Br J Cancer       Date:  2012-01-12       Impact factor: 7.640

10.  PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling.

Authors:  Luciana Bueno Ferreira; Antonio Palumbo; Kivvi Duarte de Mello; Cinthya Sternberg; Mauricio S Caetano; Felipe Leite de Oliveira; Adriana Freitas Neves; Luiz Eurico Nasciutti; Luiz Ricardo Goulart; Etel Rodrigues Pereira Gimba
Journal:  BMC Cancer       Date:  2012-11-06       Impact factor: 4.430

View more
  7 in total

Review 1.  Exosomes as divine messengers: are they the Hermes of modern molecular oncology?

Authors:  C Braicu; C Tomuleasa; P Monroig; A Cucuianu; I Berindan-Neagoe; G A Calin
Journal:  Cell Death Differ       Date:  2014-09-19       Impact factor: 15.828

2.  Role of dihydrotestosterone (DHT) on TGF-β1 signaling pathway in epithelial ovarian cancer cells.

Authors:  Karla Kohan-Ivani; Fernando Gabler; Alberto Selman; Margarita Vega; Carmen Romero
Journal:  J Cancer Res Clin Oncol       Date:  2015-06-20       Impact factor: 4.553

Review 3.  Androgen-Regulated microRNAs (AndroMiRs) as Novel Players in Adipogenesis.

Authors:  Julia Jansen; Thomas Greither; Hermann M Behre
Journal:  Int J Mol Sci       Date:  2019-11-16       Impact factor: 5.923

Review 4.  Noncoding RNAs as novel biomarkers in prostate cancer.

Authors:  C G H Rönnau; G W Verhaegh; M V Luna-Velez; J A Schalken
Journal:  Biomed Res Int       Date:  2014-08-28       Impact factor: 3.411

5.  Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression.

Authors:  Julia M A Pickl; Diana Tichy; Vladimir Y Kuryshev; Yanis Tolstov; Michael Falkenstein; Julia Schüler; Daniel Reidenbach; Agnes Hotz-Wagenblatt; Glen Kristiansen; Wilfried Roth; Boris Hadaschik; Markus Hohenfellner; Stefan Duensing; Doreen Heckmann; Holger Sültmann
Journal:  Oncotarget       Date:  2016-09-13

6.  The PCAT3/PCAT9-miR-203-SNAI2 axis functions as a key mediator for prostate tumor growth and progression.

Authors:  Fangfang Tao; Xinxin Tian; Zhiqian Zhang
Journal:  Oncotarget       Date:  2018-01-12

Review 7.  Coordinated AR and microRNA regulation in prostate cancer.

Authors:  Ieva Eringyte; Joanna N Zamarbide Losada; Sue M Powell; Charlotte L Bevan; Claire E Fletcher
Journal:  Asian J Urol       Date:  2020-06-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.